RecruitingPhase 1Phase 2NCT03011814

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

Sponsor

City of Hope Medical Center

Enrollment

78 participants

Start Date

Mar 8, 2017

Study Type

INTERVENTIONAL

Conditions

Recurrent Mycosis Fungoides Refractory Mycosis Fungoides Sezary Syndrome Folliculotropic Mycosis Fungoides Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Summary

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Durvalumab, Laboratory Biomarker Analysis, and others for people with folliculotropic mycosis fungoides, recurrent cutaneous t-cell non-hodgkin lymphoma, and other related conditions. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.